Analyst RatingAnalyst lowers the rating from Buy to Hold, seeing downside to consensus estimates.
Competition And Market RisksThere is a potential need for capital, risk from intensifying prostate cancer tissue ablation competition, and risk from EU tariffs.
Sales And Distribution StrategyEDAP plans to stop selling litho systems and reduce investment in its distribution business, expecting sales declines in these areas.